Dupilumab treatment improves health-related quality of life in patients with moderate-to-severe atopic dermatitis primarily affecting the hands (atopic hand eczema): results from a randomized placebo-controlled trial

Affiliations

¹ From the Department of Dermatology, Oregon Health & Science University, Portland, OR, USA.
² Department of Dermatology, University of Groningen, Groningen, Netherlands.
³ Division of Dermatology, Queen's University, Kingston, ON, Canada.
⁴ Department of Dermatology, University of Coimbra, Coimbra, Portugal.
⁵ Department of Dermatology, The First Hospital of China Medical University, Shenyang, China.
⁶ Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
⁷ and Sanofi, Cambridge, MA, USA. Electronic address: Ana.Rossi@sanofi.com.

Eric L Simpson et al. J Am Acad Dermatol. 2025.

. 2025 Dec 26:S0190-9622(25)03460-7.

doi: 10.1016/j.jaad.2025.12.079. Online ahead of print.

¹ From the Department of Dermatology, Oregon Health & Science University, Portland, OR, USA.
² Department of Dermatology, University of Groningen, Groningen, Netherlands.
³ Division of Dermatology, Queen's University, Kingston, ON, Canada.
⁴ Department of Dermatology, University of Coimbra, Coimbra, Portugal.
⁵ Department of Dermatology, The First Hospital of China Medical University, Shenyang, China.
⁶ Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
⁷ and Sanofi, Cambridge, MA, USA. Electronic address: Ana.Rossi@sanofi.com.

No abstract available

Keywords: atopic hand eczema; dupilumab; health-related quality of life; patient-reported outcomes.

LinkOut - more resources